Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ODAM recombinant protein is a recombinant form of the odontogenic ameloblast-associated protein (ODAM), also known as APIN. ODAM is a developmental antigen primarily involved in tooth maturation and the maintenance of junctional epithelium integrity. In oncology research, ODAM has been identified as a potential prognostic biomarker and therapeutic target, particularly in breast cancer and other epithelial malignancies. Ectopic expression or treatment with recombinant ODAM protein has been shown to moderate cell growth, increase apoptosis, and inhibit the migration and invasion of highly invasive breast cancer cells (such as MDA-MB-231) in vitro and in vivo, partially through modulating the TGF-beta signaling pathway and interacting with Runx2.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ODAM recombinant protein.